SEHK:1093
SEHK:1093Pharmaceuticals

How Investors Are Reacting To CSPC Pharmaceutical Group (SEHK:1093) Advancing New Hypertension and Diabetes Treatments

CSPC Pharmaceutical Group recently reported that its aldosterone synthase inhibitor SYH2072 secured U.S. FDA and China NMPA approvals to begin clinical trials for uncontrolled and resistant hypertension, while its fixed-dose Prusogliptin and Metformin Extended-Release diabetes therapy application was accepted by China’s NMPA. These parallel advances in hypertension and type 2 diabetes programs highlight CSPC’s push into higher-value, patent-protected treatments across major chronic disease...
SEHK:2171
SEHK:2171Biotechs

CARsgen Therapeutics Holdings SEHK 2171 Valuation After New Solid Tumor Collaboration With Dispatch Bio

Why this new collaboration matters for CARsgen Therapeutics Holdings (SEHK:2171) CARsgen Therapeutics Holdings (SEHK:2171) just announced a clinical collaboration with Dispatch Bio to run a Phase 1 trial in China, testing a combined approach for treating solid tumors using both companies' immunotherapies. The study, planned to begin in 2026, will evaluate DISP-11, which uses Dispatch's Flare platform and DV-10 tumor specific virus together with CARsgen's zevorcabtagene autoleucel, or zevor...